Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Operating Expenses (2016 - 2023)

RedHill Biopharma has reported Operating Expenses over the past 12 years, most recently at $4.8 million for Q2 2023.

  • Quarterly Operating Expenses fell 48.2% to $4.8 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $4.8 million through Dec 2024, down 75.21% year-over-year, with the annual reading at $8.2 million for FY2025, 16.03% up from the prior year.
  • Operating Expenses was $4.8 million for Q2 2023 at RedHill Biopharma, down from $6.9 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $20.6 million in Q2 2021 and troughed at $4.8 million in Q2 2023.
  • The 5-year median for Operating Expenses is $9.2 million (2020), against an average of $10.0 million.
  • Year-over-year, Operating Expenses soared 122.37% in 2021 and then plummeted 55.08% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $6.4 million in 2019, then surged by 112.48% to $13.6 million in 2020, then decreased by 8.43% to $12.5 million in 2021, then crashed by 38.78% to $7.6 million in 2022, then tumbled by 37.31% to $4.8 million in 2023.
  • Per Business Quant, the three most recent readings for RDHL's Operating Expenses are $4.8 million (Q2 2023), $6.9 million (Q1 2023), and $7.6 million (Q4 2022).